Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Key outcomes and addressing remaining challenges--perspectives from a final evaluation of the China GAVI project.

Yang W, Liang X, Cui F, Li L, Hadler SC, Hutin YJ, Kane M, Wang Y.

Vaccine. 2013 Dec 27;31 Suppl 9:J73-8. doi: 10.1016/j.vaccine.2012.09.060.

PMID:
24331024
2.

The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.

Kane MA, Hadler SC, Lee L, Shapiro CN, Cui F, Wang X, Kumar R.

Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Review.

PMID:
24331015
3.

Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation.

Cui F, Luo H, Wang F, Zheng H, Gong X, Chen Y, Wu Z, Miao N, Kane M, Hennessey K, Hadler SC, Hutin YJ, Liang X, Yang W.

Vaccine. 2013 Dec 27;31 Suppl 9:J36-42. doi: 10.1016/j.vaccine.2012.11.061.

PMID:
24331019
4.

Origins, design and implementation of the China GAVI project.

Liang X, Cui F, Hadler S, Wang X, Luo H, Chen Y, Kane M, Shapiro C, Yang W, Wang Y.

Vaccine. 2013 Dec 27;31 Suppl 9:J8-14. doi: 10.1016/j.vaccine.2012.12.019. Review.

PMID:
24331025
5.

The impact of hepatitis B vaccine in China and in the China GAVI Project.

Hadler SC, Fuqiang C, Averhoff F, Taylor T, Fuzhen W, Li L, Xiaofeng L, Weizhong Y.

Vaccine. 2013 Dec 27;31 Suppl 9:J66-72. doi: 10.1016/j.vaccine.2013.03.043.

PMID:
24331023
7.

Preventing hepatitis B though universal vaccination: reduction of inequalities through the GAVI China project.

Cui F, Liang X, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Hadler SC, Hutin YJ, Luo H, Yang W.

Vaccine. 2013 Dec 27;31 Suppl 9:J29-35. doi: 10.1016/j.vaccine.2012.07.048.

PMID:
24331017
8.

[Long-term efficacy of infant hepatitis B immunization program].

Gong J, Li RC, Yang JY, Li YP, Chen XR, Xu ZY, Liu CB, Cao HL, Zhao K, Ni DM.

Zhonghua Gan Zang Bing Za Zhi. 2003 Apr;11(4):203-5. Chinese.

PMID:
12716514
9.

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y.

Vaccine. 2009 Nov 5;27(47):6550-7. doi: 10.1016/j.vaccine.2009.08.048. Epub 2009 Sep 1.

PMID:
19729084
10.

The China GAVI Project.

Berkley S.

Vaccine. 2013 Dec 27;31 Suppl 9:J3-4. doi: 10.1016/j.vaccine.2013.02.032. No abstract available.

PMID:
24331018
11.

Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992-2005.

Cui F, Li L, Hadler SC, Wang F, Zheng H, Chen Y, Gong X, Hutin YJ, Cairns KL, Liang X, Yang W.

Vaccine. 2010 Aug 23;28(37):5973-8. doi: 10.1016/j.vaccine.2010.06.111. Epub 2010 Jul 15.

PMID:
20637773
13.

The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China.

Li F, Wang Q, Zhang L, Su H, Zhang J, Wang T, Huang D, Wu J, Yan Y, Fan D.

Vaccine. 2012 Nov 19;30(49):7118-22. doi: 10.1016/j.vaccine.2012.09.031. Epub 2012 Sep 26.

PMID:
23022150
14.

Impact of hepatitis B vaccination among children in Guangdong Province, China.

Xiao J, Zhang J, Wu C, Shao X, Peng G, Peng Z, Ma W, Zhang Y, Zheng H.

Int J Infect Dis. 2012 Sep;16(9):e692-6. doi: 10.1016/j.ijid.2012.05.1027. Epub 2012 Jul 13.

15.

Hepatitis B vaccination in children: the Taiwan experience.

Ni YH, Chen DS.

Pathol Biol (Paris). 2010 Aug;58(4):296-300. doi: 10.1016/j.patbio.2009.11.002. Epub 2010 Jan 29.

PMID:
20116181
16.

Protective immune barrier against hepatitis B is needed in individuals born before infant HBV vaccination program in China.

Yang S, Yu C, Chen P, Deng M, Cao Q, Li Y, Ren J, Xu K, Yao J, Xie T, Wang C, Cui Y, Ding C, Tian G, Wang B, Zhang X, Ruan B, Li L.

Sci Rep. 2015 Dec 14;5:18334. doi: 10.1038/srep18334.

17.

Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation.

Yang SG, Wang B, Chen P, Yu CB, Deng M, Yao J, Zhu CX, Ren JJ, Wu W, Ju B, Shen JF, Chen Y, Li MD, Ruan B, Li L.

PLoS One. 2012;7(10):e47808. doi: 10.1371/journal.pone.0047808. Epub 2012 Oct 19.

18.

Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2012 Sep 28;61:768-71.

19.

The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China.

Wang F, Shen L, Cui F, Zhang S, Zheng H, Zhang Y, Liang X, Wang F, Bi S.

Vaccine. 2015 May 28;33(23):2704-9. doi: 10.1016/j.vaccine.2015.03.064. Epub 2015 Apr 2.

PMID:
25843269
20.

An investigation of perinatal hepatitis B virus infections among a high risk population: the delivery hospital as a safety net.

Fischer G, Wang S, Ahring S, Fowler K, Hainline S, Chinglong M, Jacques-Carroll L, Bell B, Williams I.

Pediatr Infect Dis J. 2009 Jul;28(7):593-7. doi: 10.1097/INF.0b013e318196bf5c.

PMID:
19455073

Supplemental Content

Support Center